Literature DB >> 11726829

Results of simultaneous and sequential pediatric liver and kidney transplantation.

J Rogers1, J Bueno, R Shapiro, V Scantlebury, G Mazariegos, J Fung, J Reyes.   

Abstract

BACKGROUND: The indications for simultaneous and sequential pediatric liver (LTx) and kidney (KTx) transplantation have not been well defined. We herein report the results of our experience with these procedures in children with end-stage liver disease and/or subsequent end-stage renal disease. PATIENTS AND METHODS: Between 1984 and 1995, 12 LTx recipients received 15 kidney allografts. Eight simultaneous and seven sequential LTx/KTx were performed. There were six males and six females, with a mean age of 10.9 years (1.5-23.7). One of the eight simultaneous LTx/KTx was part of a multivisceral allograft. Five KTx were performed at varied intervals after successful LTx, one KTx was performed after a previous simultaneous LTx/KTx, and one KTx was performed after previous sequential LTx/KTx. Immunosuppression was with tacrolimus or cyclosporine and steroids. Indications for LTx were oxalosis (four), congenital hepatic fibrosis (two), cystinosis (one), polycystic liver disease (one), A-1-A deficiency (one), Total Parenteral Nutrition (TPN)-related (one), cryptogenic cirrhosis (one), and hepatoblastoma (one). Indications for KTx were oxalosis (four), drug-induced (four), polycystic kidney disease (three), cystinosis (one), and glomerulonephritis (1).
RESULTS: With a mean follow-up of 58 months (0.9-130), the overall patient survival rate was 58% (7/12). One-year and 5-year actuarial patient survival rates were 66% and 58%, respectively. Patient survival rates at 1 year after KTx according to United Network of Organ Sharing (liver) status were 100% for status 3, 50% for status 2, and 0% for status 1. The overall renal allograft survival rate was 47%. Actuarial renal allograft survival rates were 53% at 1 and 5 years. The overall hepatic allograft survival rate was equivalent to the overall patient survival rate (58%). Six of seven surviving patients have normal renal allograft function, and one patient has moderate chronic allograft nephropathy. All surviving patients have normal hepatic allograft function. Six (86%) of seven sequentially transplanted kidneys developed acute cellular rejection compared with only two (25%) of eight simultaneously transplanted kidneys (P<0.04).
CONCLUSIONS: Simultaneously transplanted kidneys were less likely to develop rejection than sequentially transplanted kidneys in this series. This did not have any bearing on patient or graft survival rates. Mortality correlated directly with the severity of United Network of Organ Sharing status at the time of kidney transplantation. Candidates for simultaneous or sequential LTx/KTx should be prioritized based on medical stability to optimize distribution of scarce renal allografts.

Entities:  

Mesh:

Year:  2001        PMID: 11726829     DOI: 10.1097/00007890-200111270-00016

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Transplantation of an eight-organ multivisceral graft in a patient with frozen abdomen after complicated Crohn's disease.

Authors:  Andreas Pascher; Jochen Klupp; Sven Kohler; Jan-M Langrehr; Peter Neuhaus
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

2.  Recipient survival and graft survival are not diminished by simultaneous liver-kidney transplantation: an analysis of the united network for organ sharing database.

Authors:  Eric F Martin; Jonathan Huang; Qun Xiang; John P Klein; Jasmohan Bajaj; Kia Saeian
Journal:  Liver Transpl       Date:  2012-08       Impact factor: 5.799

Review 3.  Fibrocystic liver disease: novel concepts and translational perspectives.

Authors:  Alberto Lasagni; Massimiliano Cadamuro; Giovanni Morana; Luca Fabris; Mario Strazzabosco
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

Review 4.  Combined liver and kidney transplantation in children.

Authors:  Hannu Jalanko; Mikko Pakarinen
Journal:  Pediatr Nephrol       Date:  2013-05-04       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.